Full-Time

Senior Scientist

Protein Sciences and Antibody Discovery

Confirmed live in the last 24 hours

Adaptive Biotechnologies

Adaptive Biotechnologies

501-1,000 employees

Decodes immune cell receptors for diagnostics

Biotechnology
Healthcare

Compensation Overview

$113.5k - $170.3kAnnually

+ Equity Grant + Bonus Eligible

Senior

No H1B Sponsorship

Seattle, WA, USA

Category
Bioinformatics
Biology Lab & Research
Biology & Biotech
Requirements
  • Ph.D. in Biochemistry, Chemistry, Molecular Biology, Immunology, or related fields with 5+ years of experience, or a Master’s degree with 13+ years of experience.
  • Strong scientific background in antibody discovery using immunization or display platforms.
  • Proficiency in protein design for immunization campaigns and antibody screening/engineering.
  • Expertise in recombinant protein expression systems, including mammalian, insect, and E. coli.
  • Skilled in recombinant protein and antibody purification using the AKTA system (affinity, SEC, ion exchange).
  • Experience with protein analytics (protein kinetics, epitope binning, stability) using BLI, HPLC, and DLS.
  • Competency in molecular biology techniques such as cloning, DNA and RNA extraction, and B/T cell sequencing.
  • Familiarity with molecular biology software (e.g., Geneious), molecular modeling (e.g., AlphaFold, Rosetta, Modeller), molecular visualization (e.g., PyMol), and data graphing (e.g., Prism).
  • Ability to work in a fast-paced, collaborative, cross-functional environment.
  • Experience managing work with CROs.
  • Excellent technical presentation and writing skills. Maintaining thorough records in an electronic lab notebook (e.g., Benchling).
  • Ability to work independently, adapt to shifting priorities, manage multiple tasks with short lead times, and identify and implement solutions.
Responsibilities
  • Design and purify high-quality recombinant proteins to support Antibody and TCR Discovery.
  • Conduct hands-on lab research for biophysical characterization of antibodies and other proteins.
  • Engage in antibody discovery and engineering using phage display.
  • Support Protein Sciences needs across Antibody Discovery programs and other cross-functional projects.
  • Provide strategic input into evaluating novel technologies and therapeutic modalities.
Adaptive Biotechnologies

Adaptive Biotechnologies

View

Adaptive Biotechnologies focuses on using the immune system to improve disease diagnosis and treatment. The company decodes genetic information from immune cell receptors, which are essential for the immune system's ability to identify and respond to diseases. One of their key projects is the ImmuneRACE study, which analyzes blood samples and swabs from participants to understand the immune response to COVID-19. This research aims to enhance diagnostics, treatments, and vaccines for the virus. Adaptive Biotechnologies generates revenue through partnerships with pharmaceutical companies, licensing their technology, and offering diagnostic services. Their goal is to advance healthcare by leveraging immune system data to develop better therapies and diagnostic tools.

Company Stage

IPO

Total Funding

$395.8M

Headquarters

Seattle, Washington

Founded

2009

Growth & Insights
Headcount

6 month growth

-5%

1 year growth

-11%

2 year growth

-15%
Simplify Jobs

Simplify's Take

What believers are saying

  • Adaptive Biotechnologies' partnerships with pharmaceutical companies and healthcare providers offer significant growth opportunities and revenue streams.
  • Winning the Workplace of the Year Award highlights their strong company culture and employee satisfaction, making it an attractive place to work.
  • Their collaboration with BeiGene on minimal residual disease measurement could lead to groundbreaking advancements in cancer treatment.

What critics are saying

  • The departure of key board members like Kevin Conroy and Leslie Trigg could lead to strategic instability.
  • The highly competitive biotechnology sector requires continuous innovation to maintain market position.

What makes Adaptive Biotechnologies unique

  • Adaptive Biotechnologies leverages the genetic information of immune cell receptors to develop advanced diagnostic tools and treatments, setting it apart from traditional biotech firms.
  • Their ImmuneRACE study, focusing on COVID-19 immune response, showcases their commitment to addressing current global health challenges.
  • The integration of their clonoSEQ® assay with Epic systems enhances their diagnostic capabilities, providing a seamless experience for healthcare providers.

Help us improve and share your feedback! Did you find this helpful?